| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/OXFORDJOURNALS.EURHEARTJ.A059862 |
| P698 | PubMed publication ID | 1904350 |
| P2093 | author name string | T K Nilsson | |
| J H Jansson | |||
| B O Olofsson | |||
| P433 | issue | 2 | |
| P921 | main subject | plasminogen | Q107129060 |
| P304 | page(s) | 157-161 | |
| P577 | publication date | 1991-02-01 | |
| P1433 | published in | European Heart Journal | Q2286839 |
| P1476 | title | Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris | |
| P478 | volume | 12 |
| Q40923079 | Alteplase. A reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction |
| Q60233022 | Alu-repeat polymorphism in the tissue-type plasminogen activator (t-PA) gene, t-PA levels and risk of familial myocardial infarction (MI) |
| Q38297868 | Angiotensin converting enzyme inhibitors--do they have an anti-ischemic action? |
| Q48666113 | Classic risk factors, hypercoagulability and migraine in young women with cerebral lacunar infarctions |
| Q51543758 | Defective fibrinolysis occurs after infrainguinal reconstruction. |
| Q33860684 | Dietary supplementation with highly purified eicosapentaenoic acid and docosahexaenoic acid does not influence PAI-1 activity |
| Q72897752 | Enalapril related changes in the fibrinolytic system in survivors of myocardial infarction |
| Q35224492 | Fibrin and Its Derivatives in the Normal and Diseased Vessel Wall |
| Q40492595 | Fibrinogen in Human Atherosclerosis |
| Q40582633 | Fibrinolysis and thrombosis |
| Q73681245 | Gene Polymorphisms for PAI-1 Are Associated with the Angiographic Extent of Coronary Artery Disease |
| Q40582669 | Haemostatic function, arterial disease and the prevention of arterial thrombosis |
| Q41047291 | Hemostatic factors as triggers of cardiovascular events. |
| Q24792427 | High levels of tissue plasminogen activator (tPA) antigen precede the development of type 2 diabetes in a longitudinal population study. The Northern Sweden MONICA study |
| Q77689389 | Increased levels of endothelial haemostatic markers in patients with coronary heart disease |
| Q73484494 | Increased levels of tissue plasminogen activator antigen in essential hypertension. A population-based study in Sweden |
| Q62694077 | Markers of fibrinolytic potency and clotting activation in stable angina pectoris: role of urokinase, assessment of atrioventricular differences and correlation with coronary patency |
| Q51550276 | Partially hydrogenated soybean oil reduces postprandial t-PA activity compared with palm oil. |
| Q71718204 | Pathophysiology of fibrinolysis |
| Q40636556 | Plasma concentrations of fibrinolytic factors in the subacute phase of myocardial infarction predict recurrent myocardial infarction or sudden cardiac death |
| Q33664574 | Plasmin activation system in restenosis: role in pathogenesis and clinical prediction? |
| Q50891002 | Progressive intermittent claudication is associated with impaired fibrinolysis. |
| Q54254146 | Regression of proximal deep venous thrombosis is associated with fibrinolytic enhancement. |
| Q28370997 | Relation between long-term steroid treatment after heart transplantation, hypofibrinolysis and myocardial microthrombi generation |
| Q73551754 | Relationship between serum lipoprotein(a) level and thrombin generation to the circadian variation in onset of acute myocardial infarction |
| Q73022835 | Risk factors and outcomes for atherothrombotic disease in French patients: the RIVAGE study. RIsque VAsculaire Group d'Etude |
| Q33613823 | Significance of raised plasma concentrations of tissue-type plasminogen activator and plasminogen activator inhibitor in patients at risk from ischaemic heart disease |
| Q33915910 | The fibrinolytic enzyme system. Basic principles and links to venous and arterial thrombosis |
| Q80848552 | The influence of acute-phase levels of haemostatic factors on reperfusion and mortality in patients with acute myocardial infarction treated with streptokinase |
| Q51597632 | The long-term effects of metoprolol and epanolol on tissue-type plasminogen activator and plasminogen activator inhibitor 1 in patients with ischaemic heart disease. |
| Q72650138 | Tissue plasminogen activator, plasminogen activator inhibitor-1 and von Willebrand factor in rheumatoid arthritis |
| Q33611676 | von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death |
| Q35368972 | von Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10 year follow up of survivors of acute myocardial infarction. |
Search more.